JP2018523689A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018523689A5 JP2018523689A5 JP2018508757A JP2018508757A JP2018523689A5 JP 2018523689 A5 JP2018523689 A5 JP 2018523689A5 JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018523689 A5 JP2018523689 A5 JP 2018523689A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- pharmaceutical composition
- kit
- composition according
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1514760.6 | 2015-08-19 | ||
| GBGB1514760.6A GB201514760D0 (en) | 2015-08-19 | 2015-08-19 | Compounds and method of use |
| PCT/GB2016/052575 WO2017029517A1 (en) | 2015-08-19 | 2016-08-19 | Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018523689A JP2018523689A (ja) | 2018-08-23 |
| JP2018523689A5 true JP2018523689A5 (enExample) | 2019-07-25 |
Family
ID=54258859
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018508757A Withdrawn JP2018523689A (ja) | 2015-08-19 | 2016-08-19 | ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物 |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10668077B2 (enExample) |
| EP (1) | EP3337477B1 (enExample) |
| JP (1) | JP2018523689A (enExample) |
| KR (1) | KR20180064387A (enExample) |
| CN (2) | CN108348505B (enExample) |
| AU (1) | AU2016307885B2 (enExample) |
| CA (1) | CA2995898A1 (enExample) |
| DK (1) | DK3337477T3 (enExample) |
| ES (1) | ES2939815T3 (enExample) |
| FI (1) | FI3337477T3 (enExample) |
| GB (1) | GB201514760D0 (enExample) |
| HR (1) | HRP20230376T1 (enExample) |
| HU (1) | HUE061615T2 (enExample) |
| IL (1) | IL257499A (enExample) |
| LT (1) | LT3337477T (enExample) |
| MX (1) | MX2018001926A (enExample) |
| PL (1) | PL3337477T3 (enExample) |
| PT (1) | PT3337477T (enExample) |
| RS (1) | RS64095B1 (enExample) |
| SI (1) | SI3337477T1 (enExample) |
| SM (1) | SMT202300063T1 (enExample) |
| WO (1) | WO2017029517A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010286168B2 (en) | 2009-08-20 | 2014-05-15 | Karus Therapeutics Limited | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| US10722527B2 (en) | 2015-04-10 | 2020-07-28 | Capsugel Belgium Nv | Abiraterone acetate lipid formulations |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| JP7467423B2 (ja) * | 2018-09-11 | 2024-04-15 | キュリス，インコーポレイテッド | 亜鉛結合部分を有するホスホイノシチド３－キナーゼ阻害剤との併用療法 |
| AU2019341976A1 (en) * | 2018-09-18 | 2021-04-15 | General Incorporated Association Pharma Valley Project Supporting Organization | Cancer combination therapy using quinoline carboxamide derivative |
| PT3930715T (pt) * | 2019-02-27 | 2024-08-02 | Astrazeneca Ab | Saracatinib para uso no tratamento de fibrose pulmonar idiopática |
| CN111904958B (zh) * | 2019-05-09 | 2022-09-13 | 浙江大学 | Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用 |
| GB201909468D0 (en) * | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
| WO2022105836A1 (en) * | 2020-11-19 | 2022-05-27 | Guangzhou Healthquest Pharma Co., Ltd. | Combination therapies for treating cancer |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1445742A1 (de) | 1963-11-06 | 1968-12-19 | Bayer Ag | Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen |
| US4017500A (en) | 1973-07-16 | 1977-04-12 | Schering Corporation | Certain 8-amino-1,7-naphthyridines |
| BE786081A (fr) * | 1971-07-13 | 1973-01-10 | Uniroyal Sa | Appareil et procede pour maintenir les tringles des bourrelets de pneu |
| US5703075A (en) | 1988-12-21 | 1997-12-30 | Pharmacia & Upjohn Company | Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones |
| CN1250294A (zh) * | 1999-07-27 | 2000-04-12 | 邮电部武汉邮电科学研究院 | 以太网与同步数字体系或同步光网络融合的适配方法 |
| NZ516616A (en) | 1999-08-03 | 2003-07-25 | Lilly Icos Llc | Beta-carboline pharmaceutical compositions |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| AU5261001A (en) | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| US6635640B2 (en) | 2000-06-30 | 2003-10-21 | Sugen, Inc. | 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| US6905669B2 (en) | 2001-04-24 | 2005-06-14 | Supergen, Inc. | Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase |
| ES2400339T3 (es) | 2002-07-15 | 2013-04-09 | Symphony Evolution, Inc. | Compuestos, composiciones farmacéuticas de los mismos y su uso en el tratamiento del cáncer |
| FR2846657B1 (fr) | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO2005082887A1 (ja) | 2004-02-26 | 2005-09-09 | Aska Pharmaceutical Co., Ltd. | ピリミジン誘導体 |
| CA2567883A1 (en) | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| KR20080016659A (ko) | 2005-05-20 | 2008-02-21 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로서 유용한 피롤로피리딘 |
| JP2009523812A (ja) | 2006-01-19 | 2009-06-25 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 融合へテロ二環式キナーゼ阻害剤 |
| JP5291616B2 (ja) | 2006-04-26 | 2013-09-18 | ジェネンテック， インコーポレイテッド | ホスホイノシチド３−キナーゼ抑制剤化合物およびその使用方法 |
| BRPI0710866A2 (pt) | 2006-04-26 | 2012-08-14 | Hoffmann La Roche | compostos farmacÊuticos |
| EP2035436B1 (en) | 2006-06-26 | 2011-05-25 | UCB Pharma S.A. | Fused thiazole derivatives as kinase inhibitors |
| CN101501035B (zh) * | 2006-08-08 | 2013-01-23 | 中外制药株式会社 | 作为pi3k抑制剂的嘧啶衍生物及其用途 |
| JP5313909B2 (ja) | 2006-11-13 | 2013-10-09 | アイコス コーポレイション | 炎症性疾患および癌の処置のためのチエノピリミジノン |
| AU2007334343A1 (en) | 2006-12-15 | 2008-06-26 | Ordway Research Institute, Inc. | Treatments of therapy-resistant diseases comprising drug combinations |
| AU2008210455A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
| WO2008121257A1 (en) | 2007-03-28 | 2008-10-09 | Merck & Co., Inc. | Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators |
| EP2154965A4 (en) | 2007-05-29 | 2011-08-17 | Glaxosmithkline Llc | NAPHTHYRIDINE DERIVATIVES AS P13 KINASE INHIBITORS |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| AU2008298948B2 (en) * | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| WO2010015520A1 (de) | 2008-08-05 | 2010-02-11 | Boehringer Ingelheim International Gmbh | Substituierte naphthyridine und ihre verwendung als arzneimittel |
| CA2742550A1 (en) | 2008-10-03 | 2010-04-08 | Merck Serono S.A. | 4-morpholino-pyrido[3,2-d]pyrimidines |
| GB2465405A (en) | 2008-11-10 | 2010-05-19 | Univ Basel | Triazine, pyrimidine and pyridine analogues and their use in therapy |
| US8981087B2 (en) | 2009-07-29 | 2015-03-17 | Karus Therapeutics Limited | Benzo [E] [1,3] oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors |
| AU2010286168B2 (en) | 2009-08-20 | 2014-05-15 | Karus Therapeutics Limited | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
| US20110207736A1 (en) | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| CN101849934B (zh) * | 2010-05-25 | 2011-11-09 | 苏州大学 | 一种磷脂酰肌醇-3-激酶抑制剂及其应用 |
| EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
| MY161925A (en) | 2011-07-27 | 2017-05-15 | Astrazeneca Ab | 2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer |
| WO2013017480A1 (en) | 2011-07-29 | 2013-02-07 | Cellzome Limited | Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| EP3181564B1 (en) | 2012-11-20 | 2019-09-18 | H. Hoffnabb-La Roche Ag | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
| ES2688815T3 (es) | 2013-05-10 | 2018-11-07 | Karus Therapeutics Limited | Inhibidores de histona desacetilasa novedosos |
| ES2834638T3 (es) * | 2013-05-30 | 2021-06-18 | Infinity Pharmaceuticals Inc | Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa |
| WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
| WO2015054099A1 (en) | 2013-10-08 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | Combinations of histone deacetylase inhibitors and either her2 inhibitors or pi3k inhibitors |
| US20150105383A1 (en) | 2013-10-10 | 2015-04-16 | Acetylon Pharmaceuticals, Inc. | HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma |
| GB201321729D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321730D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321728D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201402431D0 (en) * | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| MA40933A (fr) | 2014-11-11 | 2017-09-19 | Piqur Therapeutics Ag | Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514758D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514756D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compound and method of use |
| GB201909468D0 (en) | 2019-07-01 | 2019-08-14 | Karus Therapeutics Ltd | Compounds for treating cancer |
-
2015
- 2015-08-19 GB GBGB1514760.6A patent/GB201514760D0/en not_active Ceased
-
2016
- 2016-08-19 US US15/753,353 patent/US10668077B2/en active Active
- 2016-08-19 KR KR1020187007564A patent/KR20180064387A/ko not_active Withdrawn
- 2016-08-19 PL PL16756763.5T patent/PL3337477T3/pl unknown
- 2016-08-19 DK DK16756763.5T patent/DK3337477T3/da active
- 2016-08-19 CN CN201680057437.6A patent/CN108348505B/zh active Active
- 2016-08-19 HR HRP20230376TT patent/HRP20230376T1/hr unknown
- 2016-08-19 FI FIEP16756763.5T patent/FI3337477T3/fi active
- 2016-08-19 MX MX2018001926A patent/MX2018001926A/es unknown
- 2016-08-19 SI SI201631666T patent/SI3337477T1/sl unknown
- 2016-08-19 CN CN202111104917.2A patent/CN113786409B/zh active Active
- 2016-08-19 LT LTEPPCT/GB2016/052575T patent/LT3337477T/lt unknown
- 2016-08-19 CA CA2995898A patent/CA2995898A1/en not_active Abandoned
- 2016-08-19 AU AU2016307885A patent/AU2016307885B2/en not_active Ceased
- 2016-08-19 PT PT167567635T patent/PT3337477T/pt unknown
- 2016-08-19 EP EP16756763.5A patent/EP3337477B1/en active Active
- 2016-08-19 ES ES16756763T patent/ES2939815T3/es active Active
- 2016-08-19 SM SM20230063T patent/SMT202300063T1/it unknown
- 2016-08-19 WO PCT/GB2016/052575 patent/WO2017029517A1/en not_active Ceased
- 2016-08-19 JP JP2018508757A patent/JP2018523689A/ja not_active Withdrawn
- 2016-08-19 HU HUE16756763A patent/HUE061615T2/hu unknown
- 2016-08-19 RS RS20230255A patent/RS64095B1/sr unknown
-
2018
- 2018-02-13 IL IL257499A patent/IL257499A/en unknown
-
2020
- 2020-04-22 US US16/855,758 patent/US11291669B2/en active Active
-
2022
- 2022-03-01 US US17/684,020 patent/US12257254B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521979A5 (enExample) | ||
| CN111886006B (zh) | 治疗肥大细胞增多症的组合疗法 | |
| CN102105152B (zh) | 包含cdks抑制剂和抗肿瘤剂的治疗组合 | |
| US9937174B2 (en) | Combinations of histone deacetylase inhibitors and bendamustine | |
| WO2021262484A1 (en) | Combination therapy for treatment of cancer | |
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| US20160287605A1 (en) | Combination therapy | |
| JP5666910B2 (ja) | 認知機能障害を治療するためのキット、組成物、製品もしくは医薬 | |
| JP2013528600A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| JP2011513475A5 (enExample) | ||
| CN102065865B (zh) | 多发性骨髓瘤治疗 | |
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| JP5440985B2 (ja) | メラノーマの治療 | |
| SE9901573D0 (sv) | New compounds | |
| JP2015522592A5 (enExample) | ||
| EP4591940A3 (en) | Deoxy- cytidine derivatives for use in cancer therapies | |
| KR20090047552A (ko) | 진균 감염증을 치료하기 위한 제약 조성물 | |
| JP2025509278A5 (enExample) | ||
| EP2538935B1 (en) | Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine | |
| JP2016538295A5 (enExample) | ||
| SE9901572D0 (sv) | New compounds | |
| US20230060792A1 (en) | Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy | |
| US9907797B2 (en) | Combination therapies for overcoming resistance to mitotic agents during chemotherapy | |
| CN110891574A (zh) | 用于预防和/或治疗肝细胞癌的美格列明 |